At the heart of this phenomenon lies the epigenome, a sophisticated regulatory layer that influences gene expression without altering the DNA sequence itself. As we age, the epigenome undergoes significant transformations characterized by heightened levels of DNA methylation and specific histone modifications. These alterations can act as double-edged swords; while they may lead to gene silencing for protective reasons, they can also facilitate the emergence of cancerous cells. Specifically, these epigenetic changes may enable precancerous cells to exhibit distinctive hallmarks of aging, including processes like senescence and the development of the senescence-associated secretory phenotype (SASP).

Senescence, in particular, serves as a crucial biological response, where damaged cells enter a state of permanent growth arrest. While senescence can prevent the proliferation of potentially oncogenic cells, it also inadvertently creates a pro-inflammatory environment conducive to tumor progression. The SASP contributes to this effect by secreting a myriad of inflammatory cytokines, growth factors, and proteases that may, paradoxically, enhance the fitness of neighboring cells, including those carrying cancer driver mutations.

Alongside senescence, genomic instability is elevated in aging cells. The propensity for DNA damage and chromosomal anomalies increases over time, which can exacerbate the mutations already present and promote further tumorigenic evolution. The interplay between inflammation and genomic instability within the context of the aging microenvironment delineates a perilous dance that can provide the necessary conditions for malignant transformation to occur.

Moreover, as we age, the functionality of our immune system wanes—a phenomenon described as immunosenescence. This decline in immune vigilance allows mutated cells to evade detection and destruction. The immune system’s inability to adequately combat tumor cells not only facilitates cancer emergence but also enables existing tumors to flourish unimpeded. The environment surrounding these tumors, or the tumor microenvironment, becomes a hotbed of interaction between increasingly impaired immune cells and malignant cells.

This microenvironment further underscores the complexity of cancer biology, where components such as stromal cells, the extracellular matrix, and the vasculature undergo their changes during aging. These alterations can create niches that favor tumor growth. For example, compromised tissue integrity and altered metabolic functionality are observed features in aged tissues, amplifying tumor-promoting signals and exacerbating the effects of cancer driver mutations. The synergy between these factors demonstrates how the aging microenvironment can magnify the impact of genetic alterations that may otherwise remain quiescent.

Beyond the physical realm of cellular interactions, the metabolic landscape within aged tissues also skews favorably toward cancer progression. Aging cells often experience heightened metabolic stress, leading to altered energy production and nutrient utilization. This metabolic turbulence can nurture an environment skewed toward tumorigenesis, creating favorable conditions for malignant cells not just to survive, but to thrive.

These insights highlight the urgent need to unravel the intricacies of the aging tumor microenvironment and to identify the underlying mechanisms that contribute to cancer development and progression. By delineating the relationships between somatic mutations, epigenetic alterations, immune function, and the microenvironment, we can craft innovative strategies for prevention and treatment. As we deepen our understanding of how these factors interact, we can envision targeted therapies aimed at reversing age-related adaptations in cancer cells and their environments, leading to a reduction in cancer burden among older individuals.

Such work is imperative not only for extending life but for improving the quality of life in our aging population. The insights garnered from these studies provide hope for developing novel therapeutic interventions that could potentially reclaim lost regenerative capacity within aged tissues or reprogram tumor cells to make them vulnerable once again to immune detection.

Ultimately, the elucidation of these complex biological layers involved in aging and cancer offers a dual promise: not only does it pave the way for groundbreaking therapies, but it also fosters a profound understanding of the broader tapestry of human health, encompassing aging, cancer, and the intricate genetic and epigenetic dance between them.

As researchers continue to explore these domains, we stand at the precipice of significant advancements that could alter the landscape of cancer care for aged individuals, potentially leading to new paradigms that significantly diminish cancer incidence and mortality amongst older populations.

Subject of Research: The genetic and epigenetic interplay in cancer development related to aging.

Article Title: Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer.

Article References:
Easwaran, H., Weeraratna, A.T. Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer. Nat Rev Cancer 25, 828–847 (2025). https://doi.org/10.1038/s41568-025-00868-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41568-025-00868-x

Keywords: Aging, Cancer, Somatic Mutations, Tumor Microenvironment, Epigenetics, Senescence, Immune System, Genomic Instability.

At its core, lactylation represents a link between metabolism and gene expression. As cells undergo metabolic changes, particularly those associated with inflammation and immune responses, lactate levels rise. This increase in lactate is not merely a byproduct of anaerobic metabolism; rather, it serves as a signaling molecule that can alter the activity of various proteins through lactylation. This modification can affect histone proteins, the key players in the regulation of gene expression, and thus points to a mechanism by which metabolic states can influence cellular functions through epigenetic changes.

In their research, Zhu and colleagues meticulously dissect the mechanisms of lactylation and its implications for immune cells. They highlight that lactylation can modulate the activity of proteins involved in inflammation, tissue repair, and immune responses. By altering the function of these proteins, lactylation can potentiate or inhibit immune responses, leading to either protective or pathological outcomes. This insight is particularly critical for understanding the dynamics of rheumatic diseases, where immune activation plays a central role in disease pathogenesis.

One of the striking aspects of this study is the focus on rheumatic immune diseases, a category of conditions that includes rheumatoid arthritis, lupus, and scleroderma. These diseases are characterized by chronic inflammation and autoimmune responses, often leading to debilitating symptoms and severe tissue damage. By elucidating how lactylation influences immune function in these contexts, the authors propose that targeting this modification could unveil novel therapeutic strategies. Such strategies may involve modulating lactate levels or inhibiting specific lactylation events that contribute to the disease process.

Furthermore, the research underscores the potential of lactylation as a biomarker for rheumatic immune diseases. Given the profound impact of lactylation on immune cell behavior, measuring lactylation levels could provide insights into disease activity and progression. Clinical applications of this knowledge could lead to more personalized approaches in managing rheumatic diseases, ultimately improving patient outcomes. The ability to assess lactylation status may allow clinicians to tailor treatments based on a patient’s unique immunological profile, thus enhancing the precision of therapeutic interventions.

The study conducted by Zhu et al. employs advanced methodologies to investigate lactylation, integrating proteomics and genomic approaches. By employing mass spectrometry, the researchers were able to identify lactylation sites on critical proteins, elucidating the landscape of lactylation within immune cells. This high-resolution analysis is pivotal, as it not only confirms the presence of lactylation but also provides a framework for understanding its functional consequences. Following this, the integration of transcriptomic data allowed the researchers to explore how lactylation affects gene expression at a broader scale, linking metabolic signals to transcriptional outcomes.

In addition to its biochemical implications, the research opens avenues for exploring the environmental factors that may influence lactylation. For instance, the role of diet, exercise, and microenvironmental changes in modulating lactate levels and, hence, lactylation warrants further investigation. Understanding these external influences could facilitate the development of lifestyle interventions that complement pharmacological treatments, ultimately adopting a holistic approach to managing rheumatic immune diseases.

Intriguingly, the interplay between lactylation and other post-translational modifications such as methylation, acetylation, and phosphorylation adds a layer of complexity to the regulatory networks governing immune responses. The dynamic nature of these modifications suggests that the fine-tuning of immune functions is a multifaceted process, requiring a delicate balance of metabolic inputs and post-translational modifications. This interconnectedness highlights the need for a systems biology approach to fully appreciate the role of lactylation in the context of immune disorders.

As the field of immunology continues to evolve, the significance of lactylation in immune function and disease states cannot be understated. The insights provided by Zhu et al. underscore the importance of integrating metabolic and epigenetic perspectives in understanding the complexities of immune regulation. This research not only advances our knowledge of lactylation but also positions it as a critical player in the realm of immunometabolism, suggesting that further exploration could lead to paradigm shifts in how we approach the treatment of rheumatic diseases.

In conclusion, the exploration of lactylation at the intersection of immune metabolism and epigenetic regulation heralds a new era of research focused on unraveling the complexities of immune function. The evidence presented by Zhu and colleagues showcases the pivotal role of lactylation in shaping immune responses, particularly in the context of rheumatic immune diseases. This work lays the groundwork for future studies aimed at harnessing the therapeutic potential of lactylation, ultimately paving the way for innovative treatments that could significantly improve the quality of life for individuals affected by these debilitating conditions. The journey toward translating these findings into clinical practice will undoubtedly carry implications not just for rheumatic diseases but also for the broader field of immunology.

Subject of Research: Lactylation and its role in immune metabolism and epigenetic regulation in rheumatic diseases.

Article Title: Lactylation at the crossroads of immune metabolism and epigenetic regulation: revealing its role in rheumatic immune diseases.

Article References:

Zhu, Z., Huang, C., Chen, J. et al. Lactylation at the crossroads of immune metabolism and epigenetic regulation: revealing its role in rheumatic immune diseases. J Transl Med (2025). https://doi.org/10.1186/s12967-025-07498-9

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07498-9

Keywords: lactylation, immune metabolism, epigenetic regulation, rheumatic diseases, immune response, post-translational modification, disease biomarker, therapeutic strategies.

At the heart of this study lies a fundamental reconsideration of tumour heterogeneity—not merely as a collection of disparate cancer cell clones but as a continuum actively shaped by DNA integrity and epigenetic modifications. Historically, DNA damage was viewed primarily as a source of genomic instability that propels oncogenesis. However, this research delineates how varying severities and types of DNA damage do not just generate mutations but also trigger epigenetic reprogramming pathways. These epigenetic changes, encompassing histone modifications, DNA methylation, and chromatin remodeling, orchestrate the transcriptional rewiring essential for tumour adaptation and survival under hostile conditions, such as chemotherapy or radiotherapy.

By integrating single-cell analyses with sophisticated epigenomic profiling, the researchers expose a nuanced temporal and spatial heterogeneity within tumours. This heterogeneity is not static but fluid, with cancer cells oscillating between states defined by distinct DNA damage response (DDR) activities and corresponding epigenetic landscapes. The capacity of cancer cells to modulate their DDR and epigenetic profiles confers them a remarkable level of phenotypic plasticity, which underpins their fitness in diverse microenvironments. This plasticity is pivotal, enabling subsets of cells to resist apoptosis, circumvent immune detection, and metastasize.

One of the transformative insights from this work concerns the epigenetic regulation of DNA repair machinery itself. Instead of a unidirectional hierarchy where DNA damage dictates epigenetic outcomes, the study reveals a bidirectional feedback loop. Epigenetic regulators modulate the expression and activity of key DNA repair enzymes and vice versa. This crosstalk supports the emergence of subpopulations with differential repair capabilities, thus contributing to tumour evolution and the heterogeneous responses seen in clinical treatment.

Furthermore, the work highlights the role of microenvironmental stressors such as hypoxia, nutrient deprivation, and oxidative stress in exacerbating DNA damage and shaping epigenetic states. Cancer cells exploit these stress-induced modifications to enhance their survival and invasive potential. For instance, hypoxia-inducible factors (HIFs) not only influence gene expression but also coordinate DNA repair pathways and epigenetic alterations, fostering a survival advantage in metabolically challenged tumour niches.

The study’s deep dive into chromatin architecture uncovers how alterations in chromatin compaction and accessibility are not mere consequences of DNA damage but actively contribute to the regulation of gene expression programs central to tumour progression. Changes in chromatin states facilitate the activation of oncogenic pathways and the suppression of tumour suppressor genes, thereby reinforcing malignant phenotypes.

In the experimental framework, state-of-the-art CRISPR-based tools enabled precise inductions of DNA lesions, allowing the team to dissect the causal effects on epigenetic remodeling and cell fate decisions. This methodological innovation represents a milestone, providing mechanistic clarity to how localized DNA damage can remodel the epigenetic landscape, leading to differential gene expression patterns that favour tumorigenesis.

The clinical implications of these findings are profound. Resistance to therapy remains a formidable obstacle in oncology, often attributed to tumour heterogeneity. By pinpointing the molecular axes connecting DNA damage and epigenetic plasticity, this research opens avenues for novel combinatorial therapeutics. Targeting both DNA repair pathways and the epigenetic modulators may constrain the adaptability of cancer cells, thereby enhancing treatment efficacy and overcoming resistance.

Importantly, the study underscores that tumor evolution is not a simple linear accumulation of mutations but a dynamic ecological and epigenetic process. This perspective shifts the paradigm towards a more integrative view of cancer biology, where adaptation and survival are orchestrated through a complex interplay of genetic, epigenetic, and environmental factors.

Moreover, the role of epigenetic therapies in this context gains renewed interest. The reversible nature of epigenetic marks presents exploitable vulnerabilities. Drugs modulating histone deacetylases, DNA methyltransferases, and chromatin remodelers could be calibrated alongside agents affecting DNA repair, amplifying therapeutic windows and preventing tumour cells from escaping through phenotypic switches.

From a diagnostic standpoint, the identification of epigenetic and DNA damage signatures in circulating tumour DNA and single cells could herald new biomarkers that more accurately reflect tumour heterogeneity and predict treatment responses. Such biomarkers would be critical in the era of precision medicine, allowing clinicians to tailor interventions based on the dynamic state of cancer cell populations.

In exploring tumour heterogeneity further, the study also touches on how cancer stem-like cells exhibit particular DNA damage responses and epigenetic profiles that confer enhanced fitness and self-renewal capabilities. These cells act as reservoirs for tumour regeneration and are often implicated in relapse following therapy, highlighting another critical axis for intervention.

The researchers emphasize a need for longitudinal studies and more complex in vivo models to fully capture the evolving interplay between DNA damage, epigenetics, and tumour cell fitness. Such efforts will be instrumental in transitioning these fundamental insights into clinical advances and potentially curbing the high mortality associated with aggressive and resistant cancers.

In sum, this remarkable investigation elevates our understanding of cancer biology by revealing that the synergy between DNA damage and epigenetic remodeling not only fuels tumour heterogeneity but is central to maintaining cancer cell fitness. It is a clarion call for the oncology community to rethink therapeutic strategies, focusing on disruptors of this molecular interplay to undermine cancer’s adaptive prowess.

As our molecular grasp of tumour complexity deepens, the implications transcend oncology, offering paradigms for understanding other pathologies marked by cellular heterogeneity and adaptive resilience. This innovative research thus positions itself at the vanguard, shaping a future where the manipulation of epigenetic and genomic stability becomes a cornerstone in the fight against cancer.

Subject of Research: The molecular mechanisms underpinning the interaction between DNA damage, epigenetic regulation, and tumour heterogeneity that contribute to cancer cell fitness and therapy resistance.

Article Title: The interplay of DNA damage, epigenetics and tumour heterogeneity in driving cancer cell fitness.

Article References:
Rouault, C.D., Charafe-Jauffret, E. & Ginestier, C. The interplay of DNA damage, epigenetics and tumour heterogeneity in driving cancer cell fitness. Nat Commun 16, 8733 (2025). https://doi.org/10.1038/s41467-025-64445-4

Image Credits: AI Generated

Histone proteins, critical components of chromatin architecture, are subject to a variety of post-translational modifications that regulate gene accessibility. Among these, histone citrullination—a process mediated by PAD enzymes—converts arginine residues into citrulline, altering the electrostatic landscape of chromatin. PAD2, a member of this enzyme family, facilitates this conversion and thereby modulates transcriptional programs crucial for cancer cell growth. Despite the recognized role of peptidyl-arginine deiminase enzymes in various malignancies, the specific contributions of PAD2 in PDAC have remained largely undefined until now.

The team led by Professor Shinji Tanaka employed advanced genetic manipulation techniques to create pancreatic cancer cell lines with modified PAD2 expression levels. By establishing PAD2-overexpressing and PAD2-knockdown cell models, their experiments demonstrated a direct correlation between PAD2 activity and cellular proliferation rates. Cells overexpressing PAD2 exhibited accelerated growth, whereas PAD2-deficient cells showed marked proliferation attenuation. These findings underscore the enzyme’s integral role in supporting the rapid expansion of PDAC tumor cells.

Beyond cellular proliferation, the researchers elucidated mechanisms by which PAD2 influences the tumor microenvironment. RNA sequencing analyses of PAD2-knockdown cells revealed a downregulation of multiple genes, with prune exopolyphosphatase 1 (PRUNE1) emerging as a key downstream target. PRUNE1 has been implicated in oncogenic processes, and its expression appears tightly regulated by PAD2-mediated histone citrullination. This epigenetic control axis orchestrates not only tumor growth but also the immune milieu.

In vivo tumorigenesis assays provided compelling evidence of PAD2’s oncogenic potential. Mice implanted with PAD2-overexpressing pancreatic cancer cells developed significantly larger tumors, enriched with heightened levels of histone citrullination marks. Notably, these tumors presented increased infiltration of M2-polarized macrophages, immune cells known to support tumor progression through immune suppression and tissue remodeling. The interplay between PAD2 activity and immune cell recruitment suggests a multifaceted role for the enzyme in sculpting a microenvironment conducive to cancer advancement.

Therapeutically, the study explored the efficacy of PAD inhibitors in mitigating PDAC growth. Treatment of PDAC cell lines with Cl-amidine, a pan-PAD inhibitor, as well as AFM-30a, a selective PAD2 inhibitor, effectively reduced PRUNE1 expression and hampered cell proliferation. Additionally, systemic administration of Cl-amidine in mouse models bearing PAD2-overexpressing tumors substantially inhibited tumor development, highlighting the translational potential of PAD2-targeted therapies.

The association of histone citrullination with poor patient prognosis was further corroborated through immunohistochemical analyses of human pancreatic tissue samples. PDAC specimens exhibited elevated histone citrullination levels compared to normal pancreas tissue, correlating with reduced overall survival. These clinical observations reinforce the significance of PAD2-mediated epigenetic modifications as biomarkers and therapeutic targets.

This body of work advances the understanding of the epigenetic underpinnings of pancreatic cancer aggressiveness. By delineating a PAD2-PRUNE1 regulatory axis and revealing PAD2’s role in modulating both tumor cell proliferation and immune landscape, the findings cast new light on the complexity of PDAC biology. Epigenetic targeting of PAD2 enzymatic activity could therefore represent a paradigm shift in pancreatic cancer treatment, offering hope in a disease notorious for its therapeutic resistance.

Importantly, the study leverages both in vitro cell cultures and in vivo mouse models to validate the biological relevance of PAD2 in pancreatic tumorigenesis comprehensively. The integration of genetic, transcriptomic, and immunological approaches exemplifies a sophisticated experimental framework capable of unraveling intricate molecular interactions within the tumor microenvironment.

Given the dismal survival rates currently associated with PDAC, innovations in therapy are urgently required. This research suggests that pharmacological modulation of histone citrullination through PAD2 inhibition may improve patient outcomes by targeting fundamental epigenetic processes driving malignancy. Future clinical investigations will be essential to assess the safety and efficacy of PAD inhibitors as part of combination regimens in pancreatic cancer treatment.

In summary, the Institute of Science Tokyo’s study highlights PAD2 as a master regulator in PDAC progression. Its catalytic activity induces histone modifications that activate oncogenic gene expression, while simultaneously remodeling the immune contexture to favor tumor growth. This dual impact positions PAD2 as a compelling biomolecular target. As efforts to translate these findings into therapeutic applications advance, a new chapter in the battle against pancreatic cancer may be unfolding.

Subject of Research: Animals
Article Title: PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer
News Publication Date: 26-Jun-2025
Web References: https://doi.org/10.1158/1541-7786.MCR-24-1095
Image Credits: Institute of Science Tokyo
Keywords: Pancreatic cancer, Cancer, Diseases and disorders, Health and medicine, Biomedical engineering, Human health, Medical specialties

At the molecular level, the significance of lactylation pivots around its capacity to regulate both histone and non-histone proteins, thereby altering gene expression patterns and enzymatic activities relevant to lipid metabolism pathways. This modification essentially bridges the gap between metabolic status and epigenetic regulation. Novel detection and characterization methods, pioneered through advances in genetic code expansion and probe-targeted workflows, have propelled our understanding of lactylation’s biological roles forward, illuminating its nuanced involvement in metabolic diseases.

In hepatic conditions, especially non-alcoholic fatty liver disease (NAFLD), lactylation occupies a paradoxical position. On one hand, lactylation of fatty acid synthase (FASN) acts to inhibit de novo lipogenesis (DNL), effectively reducing lipid overaccumulation in hepatocytes and attenuating disease progression. Conversely, histone lactylation at specific residues such as H3K18la drives increased synthesis of triglycerides and cholesterol by upregulating genes associated with fatty acid synthesis, accelerating NAFLD’s advancement. This dual role extends to the interplay between lactylation and other epigenetic modifications such as m^6A methylation, underscoring the complexity of epigenetic crosstalk in disease etiology.

Ischemia-reperfusion injury (IRI) following liver transplantation further unravels the pathological implications of lactylation. Recent studies highlight lactylation of phosphoenolpyruvate carboxykinase 2 (PCK2) as a contributing factor to hepatocyte ferroptosis—a form of oxidative, iron-mediated cell death—which exacerbates IRI. The involvement of mitochondrial fatty acid synthesis (mtFAS) pathways in this process presents new therapeutic avenues, although clinical inhibitors remain to be developed. Targeting lactylation-modulated enzymes like PCK2 offers hope for minimizing damage during liver transplantation and potentially broadening donor organ usability.

The landscape of cancer biology has been profoundly shaped by metabolic reprogramming, with lipid metabolism at the core of tumorigenic processes. Lactylation has surfaced as a key post-translational modification maneuvering the lipid metabolic rewiring known to fuel tumor growth, invasion, and resistance to therapies. Elevated lactylation levels, both in histones and other proteins, have been implicated in malignancies such as hepatocellular carcinoma, pancreatic cancer, and pancreatic ductal adenocarcinoma. Intriguingly, specific lactylation at histone H3 lysine 18 (H3K18la) appears particularly influential in gene regulation related to oncogenesis and drug resistance, positioning it as a promising biomarker and therapeutic target.

Furthermore, resistance to chemotherapy and immunotherapy, perennial challenges in oncology, may be driven in part by lactylation-induced alterations in tumor lipid metabolism. For instance, antibodies aimed at neutralizing lactylated apolipoprotein C2 (APOC2) have shown suppressive effects on tumor progression in non-small cell lung cancer models, suggesting that targeting lactylated proteins extracellularly could complement existing treatments. Meanwhile, simvastatin’s ability to interfere with lactylation involved in the mevalonate (MVA) pathway exemplifies the potential for repurposing lipid-lowering agents to enhance cancer therapy efficacy by disrupting tumor metabolic circuits.

Vascular diseases such as atherosclerosis also display a compelling connection to lactylation-driven lipid metabolic dysregulation. The progression of atherosclerotic plaques is influenced by the lactylation state of various proteins, which in turn modulate foam cell formation, endothelial dysfunction, and inflammatory responses. Fascinatingly, lactylation has been shown to have both pro-atherogenic and protective roles depending on the cellular context and specific protein targets. For example, lactylation of MeCP2 attenuates lesion development after aerobic exercise by dampening inflammatory signaling, whereas histone lactylation mediated by the acetyltransferase P300 fosters endothelial-to-mesenchymal transition, exacerbating disease pathology. These dualistic effects imply that tailored modulation of lactylation pathways could revolutionize atherosclerosis treatment paradigms.

Metabolic disorders broadly, including obesity, diabetes, and their complications, also bear the imprint of lactylation-driven lipid reprogramming. Within the hypothalamic circuitry, histone lactylation influences neuronal pathways controlling appetite and energy expenditure, with specific marks like H4K12la linked to reduced adiposity and improved insulin sensitivity. On the other hand, lactylation of metabolic enzymes such as ACSF2 in kidneys aggravates mitochondrial dysfunction, contributing to diabetic nephropathy progression. These multi-tissue and systemic effects underscore lactylation’s role as a pivotal node in metabolic homeostasis and pathology.

Musculoskeletal degenerative diseases reveal additional dimensions of lactylation’s influence. Tendinopathies have been connected to aberrant lactylation of apolipoproteins within tendon tissues, hinting at metabolic markers for early detection and novel interventions. In intervertebral disc degeneration, the relationship between glycolytic shift, lactate accumulation, and subsequent enhancement of ferroptotic pathways through lactylation uncovers fresh therapeutic targets to slow or reverse disc aging. Similarly, lactylation-mediated modulation of key proteins in osteoarthritis establishes a metabolic link to cartilage degradation, spotlighting epigenetic regulation in musculoskeletal health.

Inflammatory diseases represent another domain where lactylation’s dichotomous nature is evident. Depending on the modification type and cellular milieu, lactylation can tip the balance between pro-inflammatory and anti-inflammatory states. In sepsis-associated acute lung injury (ALI), lactylation of histone H3K18la promotes mitochondrial damage and ferroptosis through upregulation of lipid peroxidation pathways. In parallel, specific enzyme lactylation in myocardium contributes to cardiac dysfunction in septic states. These findings hint at lactylation’s potential as both a biomarker and therapeutic target in inflammatory cascades linked to lipid metabolism.

Reproductive health disorders, including primary ovarian insufficiency (POI) and preeclampsia, have surfaced as emerging fields intersecting with lactylation and lipid metabolism. Lactylation facilitates granulosa cell proliferation and follicular development under hypoxic stress, but excessive lactylation drives premature follicle depletion, implicating it in POI pathogenesis. Furthermore, lipid-related proteins modified by lactylation in preeclampsia elucidate novel epigenetic mechanisms underlying maternal-fetal risk factors, broadening potential diagnostic and therapeutic interventions.

Neurological injury and disease, especially ischemic stroke, display complex interactions with lactylation-driven lipid metabolic regulation. The LDL receptor-related protein 1 (LRP1) modulates lactylation of ARF1 in astrocytes, influencing mitochondrial communication with neurons and affecting stroke outcomes. Additionally, lactylation of phospholipase B domain-containing protein 1 (PLBD1) exacerbates neuronal injury, whereas MeCP2 lactylation mitigates apoptosis, emphasizing the nuanced epigenetic control of neuronal survival post-insult. This bidirectional modulation advocates for therapeutic strategies seeking to harness lactylation’s neuroprotective potential.

Beyond diseases, lactylation has been implicated in specialized physiological processes such as mineralized tissue regeneration. The KDM6B/HADHA lactylation axis regulates fatty acid oxidation essential for cementum formation, with implications for dental health and regenerative medicine. Similarly, protein disulfide-isomerase lactylation emerges as a factor in radiation-induced cardiac damage, highlighting potential targets for limiting collateral tissue injury during cancer radiotherapy.

Collectively, these insights paint lactylation as a critical integrator of metabolic, epigenetic, and pathological signals in lipid-associated diseases. While research is still evolving, the identification of key lactylation sites and their corresponding enzymes opens the floodgates for innovative diagnostics and targeted therapeutics. By manipulating lactylation status, it may be possible to recalibrate disturbed lipid metabolism pathways across a spectrum of diseases—from metabolic syndromes to cancer and cardiovascular disorders—offering hope for precision medicine interventions.

However, challenges remain in fully elucidating the mechanistic intricacies of lactylation, including the identification of specific “writers,” “erasers,” and “readers,” and their tissue-specific roles. The development of selective inhibitors or mimetics, alongside advanced detection technologies, promises to accelerate translational applications. Interdisciplinary efforts blending epigenetics, metabolism, and clinical research are thus essential to unlock the therapeutic potential inherent in lactylation’s regulation of lipid metabolism.

As the field advances, a more comprehensive understanding of lactylation’s dualistic impact on disease progression and resolution will be indispensable. Close examination of its crosstalk with other epigenetic marks and metabolic pathways may reveal synergistic targets, providing novel frameworks to tackle some of the most intractable lipid-associated diseases. Ultimately, lactylation holds promise as both a biomarker for disease state monitoring and a modifiable target to alter disease trajectories across a wide biomedical spectrum.

Subject of Research: Roles of lactylation in lipid metabolism and its involvement in lipid-related diseases such as cancers, metabolic disorders, cardiovascular diseases, and reproductive system disorders.

Article Title: Roles of lactylation in lipid metabolism and related diseases.

Article References:
Zhao, B., Lan, Z., Li, C. et al. Roles of lactylation in lipid metabolism and related diseases. Cell Death Discov. 11, 401 (2025). https://doi.org/10.1038/s41420-025-02705-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02705-4